

Opicinumab

| | |
|-----------|-------------------------------------------------------------------------------------------|
| Cat. No.: | HY-P99780 |
| CAS No.: | 1422268-07-2 |
| Target: | Others |
| Pathway: | Others |
| Storage: | Please store the product under the recommended conditions in the Certificate of Analysis. |

BIOLOGICAL ACTIVITY

| | |
|---------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Description | Opicinumab (BIIB033) is a monoclonal antibody against LINGO-1 and has potential application in acute optic neuritis and relapse multiple sclerosis ^{[1][2]} . |
| IC ₅₀ & Target | LINGO-1 ^[1] |

REFERENCES

[1]. Cadavid D, et al. Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial. *Lancet Neurol.* 2017 Mar;16(3):189-199.

[2]. Cadavid D, et al. Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial. *Lancet Neurol.* 2019 Sep;18(9):845-856.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA